-
公开(公告)号：JP2012531186A
公开(公告)日：2012-12-10
申请号：JP2012516581
申请日：2010-07-01
Inventor： シズー，ハーミート , リー，キンシャン , カウリー，アーロン，ブレイク , ゴランダー，カール−グスタフ
IPC: C12N9/00 , A61K9/08 , A61K9/20 , A61K9/48 , A61K38/43 , A61K38/44 , A61K38/53 , A61K47/32 , A61P1/00 , A61P1/04 , A61P9/00 , A61P13/00 , A61P13/04 , A61P13/12 , A61P29/00 , A61P43/00 , C12N9/02 , C12N9/10 , C12N9/88 , C12N9/98 , C12N15/09
CPC classification number: C12N9/13 , C07K1/14 , C12N9/0008 , C12N9/88
Abstract: 本発明は、ヒトにおけるオキサレートの低減方法及び低減用組成物並びに組換えオキサレート低減酵素タンパク質の精製及び単離方法を含む。 本発明は、粒子組成物中のオキサレート低減酵素の送達方法及び送達用組成物を提供する。 本発明の組成物は、オキサレートに関連する状態の治療又は予防に適する。
【選択図】なし-
公开(公告)号：JP6220845B2
公开(公告)日：2017-10-25
申请号：JP2015246402
申请日：2015-12-17
Inventor： シズー,ハーミート , リー,キンシャン , カウリー,アーロン,ブレイク , ゴランダー,カール−グスタフ
IPC: C12N9/88 , C12N15/09 , A61K9/08 , A61K9/20 , A61K9/48 , A61K47/32 , A61K9/10 , A61K38/51 , A61P1/00 , A61P1/04 , A61P9/00 , A61P13/00 , A61P13/04 , A61P13/12 , A61P29/00 , A61P43/00 , C12N9/98
CPC classification number: C12N9/13 , C07K1/14 , C12N9/0008 , C12N9/88
-
公开(公告)号：JP2016121138A
公开(公告)日：2016-07-07
申请号：JP2015246402
申请日：2015-12-17
Inventor： シズー,ハーミート , リー,キンシャン , カウリー,アーロン,ブレイク , ゴランダー,カール−グスタフ
IPC: C07K1/34 , C07K1/30 , C07K1/36 , C12N9/14 , C12N9/04 , C12N15/09 , A61K9/08 , A61K9/20 , A61K9/48 , A61K47/32 , A61K9/10 , A61K38/43 , A61K38/44 , A61K38/53 , A61P1/00 , A61P1/04 , A61P9/00 , A61P13/00 , A61P13/04 , A61P13/12 , A61P29/00 , A61P43/00 , C07K1/14
CPC classification number: C12N9/13 , C07K1/14 , C12N9/0008 , C12N9/88
Abstract: 【課題】組換えオキサレート低減酵素タンパク質の精製及び単離方法を提供する。 【解決手段】可溶性の宿主細胞タンパク質から封入体として見出されない不溶性の組換えタンパク質を分離する工程と、分離した組換えタンパク質を可溶化する工程とを含む、宿主細胞の細胞質において不溶性であり、封入体として見出されない組換えタンパク質の単離法。粒子組成物中のオキサレート低減酵素及び送達用組成物。本組成物は、オキサレートに関連する状態の治療又は予防に適する 【選択図】なし
Abstract translation: 要解决的问题：提供纯化和分离重组草酸盐还原酶蛋白的方法。解决方案：本发明提供了一种分离重组蛋白质的方法，所述重组蛋白质不溶于宿主细胞的细胞质但未发现为包涵体，其包含 步骤：从可溶性宿主细胞蛋白中分离不能作为包涵体发现的不溶性重组蛋白; 并溶解分离的重组蛋白。 还提供了颗粒组合物和递送组合物中的草酸盐还原酶。 该组合物适用于治疗或预防草酸盐相关病症。选择图：无
-
4.发明申请COMPOSITIONS AND METHODS FOR THE TREATMENT OR PREVENTION OF OXALATE-RELATED DISORDERS 审中-公开用于治疗或预防与草酸相关的病症的组合物和方法
公开(公告)号：WO2017216165A1
公开(公告)日：2017-12-21
申请号：PCT/EP2017/064422
申请日：2017-06-13
Applicant: OXTHERA INTELLECTUAL PROPERTY AB
Inventor： LINDNER, Elisabeth , ÅKERMAN, Maria , SJÖGREN, Anna , MCCALLION, Orla
CPC classification number: A61K35/74 , A61K9/4866 , A61K9/4891 , A61P1/00
Abstract: The present disclosure is related to pharmaceutical compositions and methods for treating and/or preventing oxalate-related disorders. More particularly, the present disclosure pertains to compositions comprising an oxalate- degrading bacteria Oxalobacter formigenes particularly suitable for the treatment and/or prevention of late stage hyperoxaluria characterized by high plasma-oxalate levels and a progressing decrease in kidney function.
Abstract translation: 本公开涉及用于治疗和/或预防草酸盐相关病症的药物组合物和方法。 更具体地说，本公开涉及包含特别适用于治疗和/或预防晚期高草酸盐特征的草酸盐降解菌草酸甲酸甲酯的组合物，所述草酸盐降解菌特别适用于治疗和/或预防高血浆草酸盐水平和肾脏进行性降低 功能
-
公开(公告)号：WO2015002604A1
公开(公告)日：2015-01-08
申请号：PCT/SE2014/050848
申请日：2014-07-03
Applicant: OXTHERA INTELLECTUAL PROPERTY AB
Inventor： LINDNER, Elisabeth , COWLEY, Helena , COWLEY, Aaron
CPC classification number: C07K14/195 , A61K35/74 , A61K38/00 , A61K38/164 , C12N9/0006 , C12N9/0016 , C12N9/0051 , C12N9/1014 , C12N9/1085 , C12N9/14 , C12N9/88 , C12Y101/0106 , C12Y104/01016 , C12Y108/01 , C12Y201/02001 , C12Y205/01006 , C12Y205/01009 , C12Y205/01047 , C12Y303/01001 , C12Y402/01003
Abstract: The present invention relates to a secretagogue compound derived from oxalate degrading bacteria, for use in the treatment of an oxalate related disease and/or oxalate related imbalance in a subject, wherein the administration of the secretagogue results in a reduction of urinary oxalate and/or plasma oxalate in the subject. The invention further relates to a pharmaceutical composition comprising such a secretagogue compound, a method for treating a subject suffering from an oxalate related disease, and to a method for preparing a secretagogue.
Abstract translation: 本发明涉及一种衍生自草酸降解细菌的促分泌素化合物，用于治疗受试者中草酸盐相关疾病和/或草酸盐相关的不平衡，其中所述促分泌素的施用导致尿草酸盐和/或 受试者血浆草酸盐。 本发明还涉及包含这种促分泌素化合物的药物组合物，用于治疗患有草酸盐相关疾病的受试者的方法和一种制备促分泌素的方法。
-
Patent Agency Ranking
公开(公告)号：WO2020071994A1
公开(公告)日：2020-04-09
申请号：PCT/SE2019/050970
申请日：2019-10-04
Applicant: OXTHERA INTELLECTUAL PROPERTY AB
Inventor： LINDNER, Elisabeth , DEHMEL, Bastian , ÅKERMAN, Maria
Abstract: The present invention relates to the treatment or prevention of oxalate-related disorders, more particularly to the use of a pharmaceutical composition comprising Oxalobacter formigenes in the treatment or prevention of systemic oxalosis with cardiac involvement.
-
公开(公告)号：WO2015002588A1
公开(公告)日：2015-01-08
申请号：PCT/SE2013/050875
申请日：2013-07-05
Applicant: OXTHERA INTELLECTUAL PROPERTY AB
Inventor： LINDNER, Elisabeth , COWLEY, Helena , COWLEY, Aaron
CPC classification number: C07K14/195 , A61K35/74 , A61K38/00 , A61K38/164 , C12N9/0006 , C12N9/0016 , C12N9/0051 , C12N9/1014 , C12N9/1085 , C12N9/14 , C12N9/88 , C12Y101/0106 , C12Y104/01016 , C12Y108/01 , C12Y201/02001 , C12Y205/01006 , C12Y205/01009 , C12Y205/01047 , C12Y303/01001 , C12Y402/01003
Abstract: The present invention relates to a secretagogue compound derived from oxalate degrading bacteria, for use in the treatment of an oxalate related disease and/or oxalate related imbalance in a subject, wherein the administration of the secretagogue results in a reduction of urinary oxalate and/or plasma oxalate in the subject. The invention further relates to a pharmaceutical composition comprising such a secretagogue compound, a method for treating a subject suffering from an oxalate related disease, and to a method for preparing a secretagogue.
Abstract translation: 本发明涉及用于治疗受试者中草酸盐相关疾病和/或草酸盐相关失衡的衍生自草酸盐降解菌的促分泌素化合物，其中所述促分泌素的施用导致 对象中尿草酸盐和/或草酸盐的减少。 本发明进一步涉及包含这种促分泌素化合物的药物组合物，治疗患有草酸盐相关疾病的对象的方法，以及制备促分泌素的方法。
-
公开(公告)号：US20210386793A1
公开(公告)日：2021-12-16
申请号：US17282439
申请日：2019-10-04
Applicant: OXTHERA INTELLECTUAL PROPERTY AB
Inventor： Elisabeth LINDNER , Bastian DEHMEL , Maria ÅKERMAN
Abstract: The present invention relates to the treatment or prevention of oxalate-related disorders, more particularly to the use of a pharmaceutical composition comprising Oxalobacter formigenes in the treatment or prevention of systemic oxalosis with cardiac involvement.
-
9.发明授权公开(公告)号：US08940295B2
公开(公告)日：2015-01-27
申请号：US13851594
申请日：2013-03-27
Applicant: Oxthera Intellectual Property AB
Inventor： Harmeet Sidhu , Aaron Blake Cowley , Carl-Gustaf Golander , Qingshan Li
IPC: A61K38/00 , A61K38/54 , A61K38/44 , C12N9/88 , C12N9/10 , C12N9/06 , C07H21/04 , A61K38/51 , A61K9/16
CPC classification number: A61K38/51 , A61K9/1635 , A61K9/1682 , C12N9/88 , C12Y401/01002
Abstract: The present invention comprises methods and compositions for the reduction of oxalate in humans, and methods for the purification and isolation of recombinant oxalate reducing enzyme proteins. The invention provides methods and compositions for the delivery of oxalate-reducing enzymes in particle compositions. The compositions of the present invention are suitable in methods of treatment or prevention of oxalate-related conditions.
Abstract translation: 本发明包括用于还原人中草酸盐的方法和组合物，以及用于纯化和分离重组草酸盐还原酶蛋白质的方法。 本发明提供了用于在颗粒组合物中递送草酸盐还原酶的方法和组合物。 本发明的组合物适用于治疗或预防草酸盐相关病症的方法。
-
公开(公告)号：US10568946B2
公开(公告)日：2020-02-25
申请号：US15809885
申请日：2017-11-10
Applicant: OXTHERA INTELLECTUAL PROPERTY AB
Inventor： Harmeet Sidhu , Aaron Blake Cowley , Carl-Gustaf Golander , Qingshan Li
Abstract: The present invention comprises methods and compositions for the reduction of oxalate in humans, and methods for the purification and isolation of recombinant oxalate reducing enzyme proteins. The invention provides methods and compositions for the delivery of oxalate-reducing enzymes in particle compositions. The compositions of the present invention are suitable in methods of treatment or prevention of oxalate-related conditions.
-
-
-
-
-
-
-
-
-
Search Results
101
records
(took 0.024 seconds)
